Integrity Bio has developed a novel approach to achieve high concentration protein formulations including antibodies. Higher concentration generally represents smaller injection volume for reduced packaging and convenient subcutaneous injection.
At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and/or increased viscosity.
Based on underlying principles of such problems exhibited at higher concentration of proteins, Integrity Bio has achieved as high as 300 mg/mL using excipients that have been used in commercial parenteral products. Please contact us for further information and collaboration opportunities.